VIAGRA Info

A new study suggests that the drugs used to treat sexual dysfunction in men may some say also address some forms of female sexual disorders.

Medical College of Georgia researchers Kyan J. Allahdadi, Rita C. Tostes, and R. Clinton Webb say that female sexual dysfunction may partly result from inadequate supply of blood to the female genitals, and that it may be addressed with erectile dysfunction drugs.

Originally developed as therapy for hypertension, such drugs work by dilating blood vessels sufficiently to produce erections in males.

The researchers point out that these drugs have not been fully explored in females.

Using an animal model, the researchers compared the effects of three drugs used for erectile dysfunction-the phosphodiesterase 5 inhibitors (PDE5I) like sildenafil; vardenafil; and tadalafil.

The drugs were used and analysed in female and male rat internal pudendal arteries, which supply blood to the penis in men and to the vagina and clitoris in women.

The researchers observed that all the PDE5I inhibitors relaxed both female and male rat internal pudendal arteries, indicating that these arteries from both female and male rats are sensitive to PDE5I.

However, female internal pudendal arteries were more sensitive to sildenafil at a lower concentration, which suggests it may be effective at a lower dose than vardenafil.

Male internal pudendal arteries reacted more effectively to vardenafil, and female internal pudendal arteries also reacted differently in comparison to the male arteries in that they demonstrated an oscillatory behaviour by both dilating and contracting, suggesting that PDE5I may have a different mechanism of action in females.

Dr. Allahdadi said: “PDE5I may be useful in the treatment of female sexual dysfunction caused by inadequate blood supply through the internal pudendal artery. The significant difference in how male and female pudendal arteries react to PDE5 inhibitors merits further study.”

The researchers are presently exploring the different relaxation profile observed between female and male rat internal pudendal arteries as well as functional abnormalities in internal pudendal arteries from diabetic rats.

The findings of the study will be presented at the 122nd Annual Meeting of the American Physiological Society, to be held from April 18 to 22 in New Orleans.

Washington, May 19 (ANI): A new report suggests that there is no clear evidence to determine which among the three erectile dysfunction drugs-Viagra, Levitra and Cialis-works best, and which causes the least harm.

Issued by HHS’ Agency for Healthcare Research and Quality, the report said that men who took oral phosphodiesterase type 5 inhibitors, also known as PDE-5 inhibitors, had improved erectile function as compared to those who did not take the medication.

However, head-to-head trials comparing Viagra, Levitra, and tadalafil Cialis were inconclusive as to which medication worked best.

The most common short-term side effects in men taking PDE-5 inhibitors were headache, flushing, abdominal pain, and runny nose.

Although the types of reactions varied with the drugs studied, there were no significant differences in side effects associated with either Viagra, Levitra, or Cialis.

Lead reviewer Dr. Alexander Tsertsvadze, of the AHRQ-supported University of Ottawa Evidence-based Practice Center, says that more studies are needed to clarify the best treatment management options for different groups of patients as well as more clinical trials to compare PDE-5 inhibitors to hormonal, injection, and creams or other topical treatments for erectile dysfunction. (ANI)